Verdict: Arpak International Investments Limited’s March 2026 quarter was dominated by investment-accounting volatility rather than by a change in its small underlying operating income base. Quarterly income edged higher and the operating loss narrowed modestly, while the share of loss from an associated company improved sharply. Those positives were overwhelmed by a roughly Rs175.0 million impairment provision against an associated-company investment, pushing the quarter to a Rs177.1 million loss and loss per share of Rs44.27. Over the full nine months, however, the loss narrowed year on year because associate losses were much lower. The central analytical issue is therefore earnings quality: ARPAK’s reported profit can swing dramatically with associate performance and impairment reversals or charges, while its own recurring income remains small.
Company Name: Arpak International Investments Limited
Ticker: ARPAK
Reporting period: third quarter and nine months ended March 31, 2026
Reporting basis: unaudited company-level condensed interim financial statements for Arpak International Investments Limited. The statements recognize the company’s share of results from associated companies and impairment movements on associated-company investments. Pakistan Stock Exchange recorded the financial result on April 28, 2026 and the quarterly report transmission on April 29, 2026. Figures below are in Pakistani rupees unless stated otherwise.
AlphaGen readings
- Alpha QoQ Score: N/A
- TTM Performance Score: N/A
- 3Y Business Perf Score: 24.66
- Sector Leadership Score: 24.871
These four readings are AlphaGen model outputs, not company-reported financial figures. Unavailable readings are shown as N/A rather than estimated.
Results at a glance
- Third-quarter income was about Rs2.75 million versus Rs2.69 million a year earlier, an increase of roughly 2.4%.
- The third-quarter operating loss narrowed to about Rs1.09 million from Rs1.19 million, an improvement of roughly 8.6%, but the company’s own operating income base remained very small.
- The share of loss from an associated company improved sharply to about Rs0.57 million from Rs52.34 million in the comparable quarter.
- A roughly Rs174.98 million impairment provision on an associated-company investment reversed the benefit of the better associate result. The comparable quarter had included a small impairment reversal rather than a charge.
- Third-quarter loss after tax widened to about Rs177.08 million from roughly Rs47.39 million; loss per share deteriorated to Rs44.27 from Rs11.85.
- For the nine months, income was about Rs8.46 million versus roughly Rs8.89 million, while the operating loss widened to about Rs3.45 million from Rs2.94 million.
- Nine-month loss after tax narrowed to about Rs71.65 million from Rs98.48 million, and loss per share improved to Rs17.91 from Rs24.62, mainly because the cumulative share of associate losses fell substantially.
What improved
- Associated-company performance was materially less damaging. The nine-month share of associate losses fell to about Rs129.6 million from roughly Rs279.9 million, reducing one of the largest recurring pressures on reported earnings.
- The March quarter’s own operating loss narrowed modestly despite only a small increase in income, indicating somewhat better control of the company-level expense burden.
- The nine-month net loss narrowed by roughly 27%, even after the large March impairment charge, because the improvement in associate losses more than offset weaker impairment support compared with the prior year.
- The balance sheet remained overwhelmingly equity-funded, with investments representing most of the asset base rather than bank borrowing driving the financial structure.
What weakened / needs attention
- The March quarter showed how a single impairment decision can overwhelm the underlying business. A roughly Rs175 million charge was many times larger than quarterly income and operating expenses combined.
- ARPAK’s own recurring income remained too small to absorb volatility from associates. The company-level operating result stayed negative, so headline profitability still depends heavily on investment outcomes.
- The very strong December 2025 quarter was not a clean operating breakthrough. It was driven by a large impairment reversal, and much of that accounting benefit was effectively given back by the March provision.
- Current liquidity became tighter by March: current assets were slightly below current liabilities, while the asset base remained concentrated in long-term investments.
The quarter: a small operating base overwhelmed by investment accounting
The March quarter’s income line moved only modestly, to about Rs2.75 million from Rs2.69 million. Operating and general expenses remained above that income, leaving an operating loss of roughly Rs1.09 million. That was better than the Rs1.19 million operating loss in the comparable quarter, but it still shows that ARPAK’s stand-alone expense base is not covered by its recurring income stream.
The more meaningful movement occurred below operating profit. ARPAK’s share of loss from an associated company fell dramatically to about Rs0.57 million from more than Rs52 million a year earlier. If that had been the only major investment-related change, the quarter would have looked substantially better. Instead, the company recognized an impairment provision of about Rs174.98 million against an associated-company investment.
That charge drove loss before tax to about Rs176.64 million and loss after tax to about Rs177.08 million. EPS fell to negative Rs44.27 from negative Rs11.85. Economically, the quarter therefore says less about ARPAK’s day-to-day cost base than the headline loss suggests. The principal change was a reassessment of investment value, not a collapse in the roughly Rs2.7 million quarterly income stream.
Current quarter versus prior comparable
Income: Rs2.75m versus Rs2.69m — up about 2.4%
The income line was essentially stable. For an investment company of ARPAK’s structure, this small recurring amount is not sufficient on its own to explain shareholder outcomes. The key question is how much value and earnings flow from associated companies and other investments, because those items are much larger than the company’s recurring income and overhead.
Operating loss: Rs1.09m versus Rs1.19m — modest improvement
Operating expenses were still larger than income, but the deficit narrowed. This is a positive cost-control signal at the parent level, although it is not yet large enough to make the company independently profitable before associate and investment effects. A durable operating improvement would require either a larger recurring income stream, a lower fixed cost base, or both.
Associate loss: Rs0.57m versus Rs52.34m — major improvement
This was the strongest underlying improvement in the quarter. The associated-company contribution moved from a very large drag to a relatively small one. Because ARPAK’s investment portfolio and associate exposure dominate its financial position, changes in associate profitability can matter far more than movements in administrative expenses.
Impairment: a roughly Rs175m provision versus a prior reversal
The impairment line was decisive. The prior-year March quarter had benefited from a small reversal, while the current quarter recorded a very large provision. Impairment is an accounting recognition of reduced recoverable value rather than a conventional operating expense, but it is economically important because it signals a deterioration in the value attributed to an investment. It also makes quarterly EPS highly volatile and unsuitable for simple annualization.
Net result: Rs177.1m loss versus about Rs47.4m loss
The loss widened by roughly Rs130 million despite better associate performance and a slightly smaller operating deficit. That apparent contradiction is explained almost entirely by the impairment charge. The cleanest interpretation is that operating and associate trends improved, while investment valuation moved sharply against the company.
Nine-month performance: associate losses improved, but impairment support faded
For the nine months ended March 31, ARPAK generated about Rs8.46 million of income, down roughly 5% from the comparable period. The operating loss widened modestly to about Rs3.45 million from Rs2.94 million. These are meaningful movements, but they remain small relative to the investment-accounting lines that dominate reported profit.
The cumulative share of losses from associated companies improved substantially to about Rs129.6 million from roughly Rs279.9 million. That reduction of around Rs150 million was the principal reason the nine-month result improved. It was partly offset by a much smaller net benefit from impairment movements: the current nine months produced a net impairment reversal of roughly Rs61.1 million, versus about Rs184.3 million in the comparable period.
After combining those items, the nine-month loss after tax narrowed to roughly Rs71.65 million from Rs98.48 million. EPS improved to negative Rs17.91 from negative Rs24.62. The direction is better, but the result still demonstrates that ARPAK’s earnings profile is driven primarily by the performance and carrying values of its investment holdings rather than by a conventional sales-and-margin operating model.
Why the December profit did not carry into March
The half-year result had looked dramatically stronger. In the December 2025 quarter ARPAK reported profit after tax of about Rs193.37 million, even though it recorded a share of associate loss of roughly Rs102.14 million. The reason was a large impairment reversal of about Rs295.58 million. For the first six months combined, profit after tax was roughly Rs105.43 million.
The March quarter then recorded the opposite accounting movement: the associated-company loss became much smaller, but the impairment line switched to a provision of nearly Rs175 million. The result was a Rs177 million quarterly loss that erased the positive half-year profit and left the nine-month period in loss.
This sequence is crucial for interpreting ARPAK. A single quarter of positive EPS can be misleading when it is driven by a large impairment reversal, just as a single quarter of deeply negative EPS can overstate deterioration when driven by a large impairment charge. Investors need to separate recurring parent-company income, the operating performance of associates, and valuation adjustments before drawing conclusions about normalized earning power.
Balance sheet: an investment-heavy, equity-funded structure
At March 31, 2026, ARPAK’s total assets were about Rs312.52 million and long-term investments were approximately Rs272.85 million, making the investment portfolio the dominant asset. Shareholders’ equity was about Rs305.81 million, while total liabilities were small relative to equity. This is structurally different from a leveraged industrial or financial intermediary: the central balance-sheet risk is the quality and recoverable value of investments rather than refinancing of a large debt stack.
Liquidity was less comfortable. Current assets were about Rs6.16 million against current liabilities of roughly Rs6.49 million, leaving a slight current-asset deficit. Cash and short-term investments were modest relative to the long-term investment book. That does not by itself indicate financial distress, but it means the company has limited liquid resources relative to the size of assets whose value is tied up in long-term holdings.
The importance of associate accounting is also visible in equity. ARPAK has historically carried substantial revaluation-related balances linked to associated companies alongside accumulated losses. Changes in associate profitability, revaluation surplus and impairment therefore affect not only the income statement but also the composition and quality of book equity. Book value should consequently be read together with the underlying investment exposures rather than treated as a simple cash-backed figure.
What is recurring and what is not
- More recurring: the small parent-company income stream, operating and general expenses, bank charges, and the ongoing share of profit or loss from associated companies.
- Economically important but volatile: associate earnings. These recur as part of the investment model, but the magnitude can change sharply with the operating performance of the investees.
- Episodic and non-cash in the period recognized: impairment provisions and reversals. They can dominate reported EPS, but they should not be extrapolated as a steady quarterly earnings stream.
- Balance-sheet driven: revaluation-related movements and changes in the carrying value of investments can materially affect equity even when parent-company operating activity changes little.
How to read the next result
Start with the associated-company contribution. If associate losses continue to decline or turn into profit, that would improve ARPAK’s underlying investment economics more meaningfully than a small movement in parent-company administrative costs. Conversely, renewed large associate losses would again overwhelm the recurring income base.
Next, separate impairment movements from operating and associate performance. A future reversal may produce strong reported EPS without a corresponding cash inflow, while another provision may create a large accounting loss without an equivalent cash outflow. The direction and rationale for the carrying-value adjustment are more informative than simply annualizing the resulting EPS.
Then examine parent-company income and expenses. The company remains structurally reliant on investment outcomes because recurring income is only a few million rupees per quarter and the stand-alone operating result is negative. A higher-quality improvement would involve recurring income covering the parent cost base before associate and impairment effects.
Finally, monitor the balance sheet for the value and composition of long-term investments, current liquidity and changes in equity linked to associates. Because the asset base is concentrated in investments, changes in carrying values can materially alter book value and reported returns even without a conventional operating expansion.
What to monitor next
- Share of profit or loss from associated companies, because this is the most important recurring driver below the parent operating line.
- Any impairment provision or reversal on associated-company investments, including the stated reason and size relative to the investment carrying value.
- Parent-company recurring income versus operating and general expenses, to see whether the stand-alone cost base moves toward break-even.
- Long-term investment carrying values and any material changes in the composition of the portfolio.
- Current assets, current liabilities and liquid balances, especially if investment commitments or distributions change.
- Changes in revaluation-related reserves and accumulated losses that materially alter the quality or composition of shareholders’ equity.
Overall, ARPAK’s March 2026 result is a strong example of why investment-company earnings must be decomposed before they are interpreted. The parent operating deficit improved slightly and the associate loss fell sharply, but a large impairment charge turned those positives into a severe quarterly loss. Over nine months, the picture was less negative because associate losses improved enough to narrow the cumulative loss. The next result will be most informative if associate performance stabilizes and impairment volatility subsides, allowing the recurring economics of the investment portfolio to become clearer.
Sources
- Arpak International Investments — Financial Results, quarter and nine months ended March 31, 2026
- Arpak International Investments — Quarterly Report, March 31, 2026
- Arpak International Investments — Half-Year Results, December 31, 2025
- Arpak International Investments — Annual Report 2025
- Pakistan Stock Exchange — ARPAK profile and announcements